ArticleOpen forum infectious diseases2025

Phase 1 Randomized Controlled Trial of the Safety and Immunogenicity of the SARS-CoV-2 (Omicron BA.5) mRNA-CR-04 Vaccine in Adults 18-49 Years of Age.

Abdi Naficy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.